Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

ImmunoOncology M & A Cancer

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.

Gynecology & Urology Clinical Trials Research & Development

Compliance Continues To Curtail Effective Asthma Treatment

The top two high-priority challenges to address in asthma treatment for respondents to a large survey by Datamonitor Healthcare of pulmonologists and primary care physicians in the US, Japan and Europe were improving compliance and developing effective, easy-to-use inhalers.

Respiratory Compliance Cost Effectiveness
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Set Alert for Commercial

Takeda Catches Rising Tide Of Antisense Neuroscience R&D

Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.

Deals Neurology Commercial

BrainStorm Cell Therapeutics Seeks JVs And Investors To Commercialize Stem Cell Pipeline

Chaim Lebovits, president and CEO of BrainStorm Cell Therapeutics, discusses the company's stem cell trials in ALS and other ventures in the pipeline.
StartUps and SMEs Regenerative Medicine Research and Development Strategies

Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition

The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.

Commercial Deals

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Clinical Trials Research and Development Strategies

Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?

Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.

Commercial Companies

Osteoarthritis Stem Cell Therapy Could Be On Sale In India By 2020

A novel Indian stem cell injection treatment intended to slow down joint damage caused by osteoarthritis and potentially avert replacement surgery will undergo domestic Phase III trials this year and could be on sale in the country by 2020 under a licensing deal between Alkem Laboratories and biotech firm Stempeutics.

Commercial Deals

Can Sanofi’s Toujeo Prickle Tresiba In India?

Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.

India Pricing Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

US FDA Advisory Cmte. Review Of Charleston's Hydexor Exposes Flaws In Commercial Strategy

Physicians may be hesitant to prescribe the opioid/anti-emetic combo for several reasons; panelists were concerned the company hasn't figured out a specific commercial audience for Hydexor at this point in the review process.
Advisory Committees Neurology Regulation

Richter Expects Esmya Sales To Drop 50% Following EU Restrictions Over Liver Concerns

Restrictions placed on the use of Gedeon Richter’s uterine fibroid drug Esmya by the European Medicines Agency could significantly dent the product’s sales in the EU, and could also have a knock-on effect in the US, where the FDA accepted an NDA filing for the drug in October 2017.

Drug Safety Drug Review

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
ImmunoOncology Cancer

FDA Deputy On CRLs: 'It's Not Our Property To Release'

US FDA Principal Deputy Commissioner Rachel Sherman said during the BIO CEO & Investor conference that while investors and others would like to see complete response letters, the agency's hands are bound when it comes to their full release. Sherman also commented on FDA's focus for right-to-try legislation.

FDA Complete Response Letters

Research & Development Explore this Topic

Set Alert for Research & Development

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Dermatology Research and Development Strategies Market Access

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Clinical Trials Research and Development Strategies

Aimmune Accelerates Commercial Planning For Peanut Allergy Drug

Even better than expected efficacy and safety in the Phase III PALISADE trial puts Aimmune on track to file its BLA for peanut protein capsule AR101 by the end of 2018.

Clinical Trials Immune Disorders

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Research & Development Deals
UsernamePublicRestriction

Register

Advertisement